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As our understanding of how molec-ular machineries work expands, 
an increasing number of proteins that 
appear as regulators of different pro-
cesses have been identified. These 
proteins are hubs within and among 
functional networks. The 14-3-3 protein 
family is involved in multiple cellular 
pathways and therefore influences sig-
naling in several disease processes, from 
neurobiological disorders to cancer. As 
a consequence, 14-3-3 proteins are cur-
rently being investigated as therapeutic 
targets. Moreover, 14-3-3 protein levels 
have been associated with resistance to 
chemotherapies. There are seven 14-3-3 
genes in humans, while Caenorhabditis 
elegans only possesses two, namely par-5 
and ftt-2. Among the C. elegans scientific 
community, par-5 is mainly recognized 
as one of the par genes that is essential for 
the asymmetric first cell division in the 
embryo. However, a recent study from 
our laboratory describes roles of par-5 
in germ cell proliferation and in the cel-
lular response to DNA damage induced 
by genotoxic agents. In this review, we 
explore the broad functionality of 14-3-3 
proteins in C. elegans and comment on 
the potential use of worms for launch-
ing a drugs/modifiers discovery platform 
for the therapeutic regulation of 14-3-3 
function in cancer.
Introduction
As genetic studies progress, the concept of 
“genetic pathways” tends to become obso-
lete and instead, sophisticated “genetic 
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networks” arise as central controls of 
cellular and developmental processes. 
Within these networks, there are genes 
interconnecting nodes of a specific cellu-
lar or developmental process (party hubs) 
or genes that works as higher-level con-
nectors of different functional modules 
(date hubs).1 While there is an ongoing 
active debate about the meaning of these 
terms, a recent study suggests that party 
and date hubs are not exclusive.2 14-3-3 
proteins form homo- and heterodimers 
that bind many phospho-Serine and 
phospho-Threonine-containing ligands 
to participate in the regulation of diverse 
functional networks. The interaction with 
14-3-3 proteins is required to control sta-
bility, subcellular location, and activity of 
these phosphorylated ligands. Since there 
are seven 14-3-3 genes in humans (β, γ, 
ε, ζ, η, σ, and τ), and most of them are 
ubiquitously expressed, a wide range of 
influence in human physiology can be 
expected. In that regard, the existence of 
only two 14-3-3 genes in C. elegans (par-5/
ftt-1 and ftt-2) helps to study hallmark 
functions of the family. In addition, par-5 
is the only 14-3-3 gene expressed in the 
worm germline, while both ftt-2 and par-5 
are expressed in the soma.3 Therefore, 
by characterizing the role of par-5 in the 
worm germline, we may be exploring the 
core functions of the protein family in 
germ cells through evolution. A search 
in Pubmed in July 2012 identified 4,000 
publications related to 14-3-3 proteins, 
and one quarter of those entries also con-
tained the term “disease,” which under-
scores the relevance of this protein family 
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have added insight into the growing list 
of PAR-5 functions in C. elegans develop-
ment and physiology by describing its role 
in germ cell proliferation and DNA dam-
age response.7
In summary, higher or lower PAR-5 
levels affect different biological pro-
cesses or functional modules that are 
somehow related at the organism level. 
Future research will determine how these 
diverse PAR-5 functions are connected. 
Therefore, since PAR-5 regulates mul-
tiple functions by interacting with many 
proteins at distinct tissues, it may also be 
termed a “date hub.”
Influence of PAR-5 in the  
Cell Cycle and DNA Damage  
Response: Levels, Levels, Levels
As the list of PAR-5 functions expands, 
fine genetic approaches for dissecting out 
those functions are required. The power 
of biochemistry is diluted in multicellular 
organisms, where protein-protein interac-
tions can vary between cell types. In this 
regard, biochemical studies may be noisy 
and too much of a reductionist approach. 
The amenability of C. elegans genetics to 
disrupt gene expression at different levels 
as well as at different lineages is an extraor-
dinary tool that can be used to explore the 
diverse roles of multifunctional proteins. 
RNAi is an essential ingredient in any of 
these knockdown recipes. In our study, 
we worked with two different levels of 
par-5 inactivation, including the use of a 
hypomorphic allele (point mutation, allele 
it55) that produces a reduction in PAR-5 
levels, and an RNAi protocol that caused 
greater protein depletion. This approach 
allowed us to find that two different par-5 
expression levels are required for distinct 
par-5 functions in the germline (Table 1). 
Based on those results, it was clear that a 
mild decrease in PAR-5 levels is enough to 
affect the extrinsic DNA damage-induced 
checkpoint response, whereas a stronger 
depletion of the protein affects germ cell 
cycle progression and DNA stability. The 
correlation between the par-5 levels and 
germline defects was further confirmed 
by two observations: (1) the attenuated 
phenotypes observed when par-5 RNAi 
was either diluted or administrated at 
later stages of development, and (2) the 
seems to be unique among PAR fam-
ily members. Furthermore, we showed 
that par-5 is required for checkpoint-
mediated delay of the first embryonic 
cell cycle in response to replicative stress. 
The checkpoint pathway contributes to 
asynchronous cell division occurring at 
the two-cell stage,8 but par-5 suppression 
produces synchronous cell division of the 
two-cell embryo.5 Therefore, par-5 has at 
least two separate roles in early embry-
onic development: one in asymmetric 
division and other in the regulation of 
cell cycle timing. Accordingly, PAR-5 
could be a link between PAR family 
functions and embryonic cell cycle regu-
lation as a mechanism for proper deter-
mination of cellular fates in the early 
embryo. Consequently, PAR-5 could be 
defined as a “party hub,” or a local coor-
dinator in the process of the first embry-
onic division.
However, par-5 has many other essen-
tial functions in the organism. Using 
co-immunoprecipitation and immuno-
fluorescence experiments, PAR-5 was 
found to interact with MAU-8, which is 
a protein required for G-protein signal-
ing that regulates diverse physiological 
functions and behavior in C. elegans.9 
Using Yeast Two Hybrid and co-immu-
noprecipitation assays, it was shown that 
PAR-5 and FTT-2 interact with LET-
756, which is one of the two Fibroblast 
Growth Factors (FGFs) in C. elegans and 
is essential for development.10 PAR-5 and 
FTT-2 are binding partners of SIR-2.1 
and are required for the life span exten-
sion conferred by high levels of SIR-2.1.11 
These interactions are also functionally 
related to the stress response mediated by 
SIR-2.1 and DAF-16. Moreover, PAR-5 
and FTT-2 also interact with DAF-16, 
and overexpression of either of the two 
C. elegans 14-3-3 proteins extends life 
span in a daf-16-dependent manner.12 
However, the role of PAR-5 in aging is 
still controversial, since more recent stud-
ies underscore FTT-2 as the main 14-3-3 
protein regulating lifespan, DAF-16 sub-
cellular location, and expression of DAF-
16 downstream targets.13,14 Finally, it has 
been recently reported that PAR-5 plays a 
role in apicobasal cell polarity in intestinal 
cells by regulating the polarized location 
of endosomes and F-actin.15 Moreover, we 
in biomedical research. However, there is 
still a limited understanding of the conse-
quences of altered 14-3-3 function at the 
organism level.
PAR-5: Polarity and  
Many Other Things
Although the previous name of par-5 
was ftt-1 (14-three-three-1), the extensive 
research on the first embryonic division 
favored the use of par-5. The C. elegans 
first embryonic division is asymmetric 
and establishes the anterior-posterior axis 
that is essential for specifying the fates of 
daughter cells. Several genes known as par 
genes (from partitioning defective) have 
been found to be indispensable for this 
asymmetric cell division.4 The asymme-
try of this division is not only due to the 
different size of daughter cells, but also to 
differential segregation of cell determi-
nants. In 2002, Morton et al. showed that 
although PAR-5 is not asymmetrically 
distributed in the one-cell embryo, it is 
required for the asymmetric cortical local-
ization of other PAR proteins and cell fate 
factors, such as MEX-5 and P-Granules, 
and is essential for the establishment of 
distinct posterior and anterior domains.5 
In addition, during early embryonic stages, 
PAR-5 regulates the asymmetric nucleic 
enrichment of the transcription factor 
POP-1 upon WNT signaling, which is 
required for endoderm cell fate determi-
nation.6 In support of these essential func-
tions in the embryo, par-5 mutants display 
embryonic lethality.5
Interestingly, beside the previously 
described functions of par-5 in the 
embryo, our recent manuscript provided 
additional information regarding the role 
of par-5 in the embryonic cell cycle.7 By 
measuring the cell cycle length at the first 
embryonic division, we found that par-
5-defective embryos presented a shorter 
S-phase and a longer M-phase, suggesting 
that par-5 is involved in the regulation of 
the embryonic cell cycle. At first sight, 
this cell cycle defect could be explained as 
a consequence of the impaired asymme-
try, and therefore it should be observed 
after the suppression of other par genes. 
However, by analyzing videos from the 
Phenobank (www.worm.mpi-cbg.de), 
we found that such a cell cycle alteration 
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in worms by studying: (1) the effect of 
higher or lower levels of PAR-5 and FTT-2 
in cell proliferation during different C. 
elegans developmental stages, and (2) the 
redundant or specific functions of PAR-5 
and FTT-2 in somatic tissues where they 
are co-expressed.
Another mechanism by which 14-3-3 
proteins influence cancer development 
is through apoptosis by interacting with 
BCL-2 family members.24,25 14-3-3 pro-
teins bind several effectors of apoptosis 
and inhibit their pro-apoptotic functions. 
As a consequence, 14-3-3 proteins have 
an anti-apoptotic effect that may con-
tribute to tumorigenesis. In C. elegans, 
physiological apoptosis can be stud-
ied either in the embryo or in the adult 
germline during oogenesis. We did not 
observe obvious alterations in apoptosis 
in the hypomorphic mutant (it55 allele), 
and our par-5 RNAi protocol severely 
impaired oocyte formation, which ham-
pered the study of apoptosis. Therefore, a 
specific RNAi protocol needs to be opti-
mized in order to study the role of par-5 
in physiological apoptosis. Nevertheless, 
we observed nuclear fragmentation in 
proliferating germ cells of par-5 RNAi 
animals that resembles mitotic catas-
trophe, which is a process that leads to 
apoptosis. However, such fragmenta-
tion was triggered by premature mitotic 
entry, rather than by deregulation of 
pro-apoptotic proteins.
proteins (over 200) and thereby regulate 
their activity, and some of these binding 
partners are proteins with active roles 
in tumorigenesis, such as Raf proteins, 
FOXO1, and components of the TORC1 
and β-catenin signaling pathways.19 Such 
is the promiscuity of 14-3-3s to interact 
with proteins that both pro-proliferative 
roles and tumor suppressor activities have 
been attributed to this family, depending 
on the cellular context.20 For the sake of 
simplicity, 14-3-3s have been divided in 
two groups according to their role in can-
cer: 14-3-3σ is a tumor suppressor, while 
the remaining 14-3-3 family members 
are oncogenes.21
14-3-3σ, is expressed primarily in epi-
thelial cells, which is in contrast to other 
family members.22 It is cataloged as a 
tumor suppressor because it positively 
regulates p53 and is also required for 
the G2/M checkpoint upon DNA dam-
age.23 However the contribution of 14-3-
3σ to tumorigenesis needs to be further 
explored. Other reports have associated 
14-3-3σ expression with poor prognosis 
of diverse types of cancer, but this effect 
could be related to its role in chemoresis-
tance. On the other hand, 14-3-3ζ over-
expression has been detected in multiple 
cancers, and it has been suggested that 
this protein regulates signaling during 
cancer initiation and progression.21 In 
this sense, it will be interesting to investi-
gate these dual roles of the 14-3-3 family 
stronger phenotypes observed when treat-
ing par-5 hypomorphic mutants with 
par-5 RNAi. Nevertheless, the functional 
dissection of a 14-3-3 protein could be 
assessed further in a multicellular organ-
ism such as C. elegans by using RNAi 
approaches of different strengths through 
microinjection or by feeding with diluted 
dsRNA. Moreover, since there are strains 
that allow for lineage- or tissue-specific 
RNAi induction,16-18 researches have the 
opportunity to choose multiple options 
for exploring the function of a multitask 
protein such as PAR-5.
To complete the range of par-5 levels 
that can be studied in C. elegans, we have 
made a transgenic strain carrying a trans-
lational construct of PAR-5 in frame with 
GFP [par-5 promoter::GFP::par-5 ORF + 
par-5 3'UTR] (Fig. 1A). This transgenic 
worm was generated by gene bombard-
ment, and since the transgene is trans-
mitted to 100% of the progeny, it may 
be integrated in the genome. However, 
we were not able to detect PAR-5:GFP in 
the germline, although the GFP signal is 
very bright in somatic cells. This is most 
likely due to silencing of exogenous DNA 
in the germline. As a consequence, we did 
not mention the existence of this trans-
genic animal in our publication because 
it was irrelevant for studies of the germ-
line. However, this strain can be useful 
for studying the effect of higher PAR-5 
levels (assuming that the PAR-5 protein 
tagged with GFP is functional) in the che-
moresistance of somatic cells or in aging. 
Moreover, this transgenic could be a valu-
able tool to study how 14-3-3 expression 
and subcellular localization are regulated 
by other pathways, physiological signals, 
or putative therapeutic small molecules 
(Fig. 1B).
The Use of Worms to Unravel the 
Roles of 14-3-3 Proteins in Cell 
Proliferation and Apoptosis
Since 14-3-3 proteins participate in many 
signaling networks, abnormal 14-3-3 
functions and also deregulation of 14-3-3/
partner interactions contribute to differ-
ent types of diseases. 14-3-3 proteins self-
assemble into homo- and heterodimers 
with other family members. These 14-3-3 
dimers can interact with many other 





Germline proliferation defects +/- ++
DNA damage in mitotic germ cells - +
DNA damage in meiotic germ cells - +
Meiotic progression defects - +
Sterility - +
Upon exogenous DNA damage
Checkpoint defects in germ cells + +
Checkpoint defects in embryo + +
Premature mitotic entry in germ cells + +
Phenotypes observed in par-5(it55) mutants vs. par-5 RNAi-treated animals. Phenotypes were 
examined in worms without any treatment (unchallenged worms), or worms treated with DNA 
damaging agents like Hydroxyurea, Ionizing Radiation and Camptothecin (exogenous DNA dam-
age). According to their penetrance, phenotypes were classified as: strong (++), evident (+), mild 
(+/-) or absent (-).
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indicates that this is a mechanism that 
seems to be conserved from worms to 
humans.7 Several studies have shown a 
correlation between high 14-3-3 levels 
and drug resistance. 14-3-3σ is one of 
the proteins that is upregulated in drug 
resistant cell lines, including breast can-
cer and pancreatic adenocarcinoma.27,28 
Accordingly, overexpression of 14-3-3σ 
makes certain cell lines more resistant to 
chemotherapeutic drugs, such as cisplatin 
or gemcitabine.23,29 Conversely, 14-3-3σ 
depletion is correlated with increased sen-
sitivity of colorectal cancer cells to doxo-
rubicin-induced apoptosis.30 This effect 
on chemoresistance within the 14-3-3 
family does not seem to be exclusive for 
14-3-3σ. 14-3-3ζ was shown to mediate 
the resistance of lymphomas to anthra-
cycline-based chemotherapies. Moreover, 
higher 14-3-3ζexpression is induced by 
tamoxifen, and this effect may lead to 
tamoxifen resistance in breast cancer.31,32 
In addition, cancer treatment using doxo-
rubicin and epirubicin has been shown to 
be less effective in tumors that overexpress 
14-3-3ζ.33 Other 14-3-3 isoforms have also 
been shown to be involved in chemoresis-
tance, either in cell lines or in patients.34,35 
However, one recent study has shown that 
14-3-3σ is downregulated in 5-fluoroura-
cil (5-FU)-resistant breast cancer cells.36 
This finding seems to be an exception, 
since 14-3-3 upregulation is correlated 
with resistance after most chemotherapeu-
tic treatments.
The contribution of 14-3-3 proteins in 
the resistance to DNA-damaging drugs 
has been mainly associated with their func-
tion in suppressing cell death pathways, 
such as by regulating the pro-apoptotic 
protein BAD.25,37 However, this resistance 
may also be related to its role in regulat-
ing the cell cycle checkpoint after DNA 
damage.23,38 In support of this hypothesis, 
colorectal cancer cells fail to arrest at G2 
upon DNA damage, but undergo mitotic 
catastrophe if 14-3-3σ is inactivated.39,40 
This observation is very interesting, since 
we have found the same effect upon par-5 
inactivation in Hydroxyurea- or Ionizing 
Radiation-treated worm germ cells. 
Therefore, the correlation between low 
14-3-3 levels and increased sensitivity to 
DNA damaging chemotherapeutic agents 
is conserved from worms to humans. This 
partners could be of great interest to tackle 
cancer progression.
Chemoresistance  
as a Family Business
14-3-3 levels are also relevant to the 
resistance or sensitivity to chemothera-
pies, and interestingly, our recent study 
Therefore, although it is evident 
that 14-3-3s have a profound impact in 
cancer progression, such impact is com-
plex. Despite this complexity, 14-3-3 
proteins still present high interest as 
therapeutic targets.26 Small molecule 
inhibitors that broadly affect 14-3-3 
interactions or specifically inhibit inter-
actions of 14-3-3 with certain binding 
Figure 1. (A) Adult transgenic worm expressing a GFP::PAR-5 transgene. Images were taken using 
Nomarski optics (on the left) and fluorescence microscopy (on the right). The transgene is widely 
expressed in somatic lineages but silenced in the germline as in embryos. At the subcellular level, 
GFP::PAR-5 location is cytoplasmic in several cell types as ganglia neurons in the tail. These neu-
rons at the highlighted region are showed at higher magnification (white box). (B) C. elegans as a 
model to screen for genes related to 14-3-3s and for drugs modifying 14-3-3 activity.
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neck in the understanding of their global 
functions. Many of these proteins, iden-
tified through proteomic approaches, are 
potential binding partners, but these inter-
actions require a functional validation. It 
is now even clearer that core 14-3-3 func-
tions are conserved through evolution, 
and therefore C. elegans is an extraordi-
nary model to validate binding interac-
tions assessing their capacity to phenocopy 
14-3-3 inactivation or modify 14-3-3 
functions (Fig. 1B). A drug that broadly 
modifies 14-3-3 interactions would be 
beneficial for certain diseases and chemo-
therapies, and the search of such a drug 
would begin in a model organism like 
C. elegans that possesses only two 14-3-3 
proteins, which may represent the core 
functions of all family members (Fig. 1B). 
Finally, genetic engineering techniques 
based on the mos-1 transposon allow spe-
cific gene substitution in C. elegans.45 In 
that sense, a worm could be “humanized” 
for a specific 14-3-3 protein, for example 
by exchanging par-5 with 14-3-3σ, in 
order to screen for drugs affecting only 
the 14-3-3 homodimer of interest. This 
replacement using different 14-3-3 genes 
could also allow for the identification of 
the individual contributions of 14-3-3 iso-
forms to the cell cycle and DNA damage 
response pathways, which in other words, 
would help to check the functional redun-
dancy of family members.
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feature can be exploited as a strategy in 
worms for exploring approaches for treat-
ing human tumors that become resistant 
to certain DNA-damaging therapies.
Future Directions
In summary, 14-3-3s play key roles in 
cancer-related processes, both in cancer 
progression and in the regulation of the 
sensitivity to chemotherapeutic agents. 
Crystal structures of all seven mamma-
lian 14-3-3 proteins have been solved, 
and this information has facilitated the 
prediction of interactions with small mol-
ecules. However, the fact that 14-3-3s 
could interact with hundreds of proteins 
increases the probability of side effects for 
these potential drugs. Still, approaches for 
developing drugs that inhibit or modulate 
14-3-3 functions are ongoing. One of the 
first attempts to inhibit 14-3-3 function 
led to the identification of a high affin-
ity 14-3-3 agonist, the R18 peptide. R18 
competes with natural client proteins 
for binding at the 14-3-3 amphipathic 
groove, and inhibits all 14-3-3 isoforms.41 
However, more recently, the search has 
been focused on identifying non-peptidic 
inhibitors. For instance, Cotylenin A, 
which is a fungal metabolite, has been 
found to modify 14-3-3 interactions, 
and further derivatives of this drug could 
be synthesized in order to confer speci-
ficities for individual 14-3-3/target pro-
tein complexes.42 Another non-peptidic 
inhibitor, called BV02, has been found 
by virtual screening to sensitize leukemia 
cells in response to imatinib treatment.43 
Chemical screenings have also identified 
a small 14-3-3 inhibitor molecule named 
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